BUY MELANOTAN-2 (10 MG/VIAL – 1 VIAL)
MAIN PRODUCT DESCRIPTION
Product Overview & Pharmaceutical Specifications
Melanotan-2 10 mg/vial is described in the supplied information as a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH). It belongs to the melanocortin family and has been investigated for its ability to interact with several melanocortin receptor subtypes.
The supplied presentation contains 10 mg of lyophilised powder per vial and is identified as an injectable preparation requiring reconstitution. The source associates Melanotan-2 with pigmentation-related and erectile-function research.
Product Specifications
Product: Melanotan-2
Strength: 10 mg/vial
Active Ingredient: Melanocortin
Chemical Name: Ac-cyclo[Nle4, Asp5, D-Phe7, Lys10]α-MSH4-10-NH₂
Dosage Form: Lyophilised powder for reconstitution
Route: Injection
CAS Number supplied: 121062-08-06
Pharmacological Class: α-MSH mimetic / melanocortin analogue
Market Status supplied: Prescription
Manufacturer: Hilma Biocare, India
Distributor: Rein Farmacie, Belgium
Storage: 2–8°C; do not freeze; protect from direct sunlight
No molecular formula or molecular mass was supplied for the product, so these details have not been added.
Melanotan-2 is described as an α-MSH mimetic. Alpha-MSH is a naturally occurring melanocortin peptide that interacts with melanocortin receptors involved in pigmentation, energy regulation and other physiological processes.
The melanocortin receptor family includes MC1R, MC2R, MC3R, MC4R and MC5R. The supplied source describes Melanotan-2 as relatively non-selective and capable of activating multiple receptor subtypes.
Different receptor subtypes are associated with different biological functions. In particular, MC1R signalling is strongly associated with melanin production and pigmentation, while MC4R signalling is involved in central nervous-system pathways that can influence sexual and metabolic functions.
Pigmentation Pathway
Activation of MC1R on melanocytes can increase melanin production. Melanin is the pigment responsible for much of the colour of skin, hair and eyes.
The supplied source describes Melanotan-2 as capable of increasing skin pigmentation through melanocortin-receptor activity.
However, the source’s claim that Melanotan-2 prevents skin cancer caused by sunlight should not be presented as an established protective effect. Increased pigmentation does not eliminate the risks associated with ultraviolet radiation, and Melanotan-2 should not be promoted as a substitute for established sun-protection measures.
Erectile-Function Research
The supplied source also describes potential activity involving MC4 receptors and penile erection.
Melanocortin signalling in the central nervous system has been studied in relation to sexual-function pathways. The source contrasts Melanotan-2 with PT-141 (bremelanotide), describing PT-141 as more selective for MC4-related activity.
These biological observations should remain within their research context. They do not establish Melanotan-2 as an approved treatment for erectile dysfunction.
Receptor Selectivity
The supplied material distinguishes Melanotan-2 from more selective melanocortin compounds.
According to the source, Melanotan-2 can activate several melanocortin receptor subtypes rather than acting exclusively at one receptor. This broader receptor activity is relevant because the different melanocortin receptors participate in distinct physiological pathways.
Consequently, the effects of Melanotan-2 cannot be reduced to pigmentation alone.
Research into Metabolic Effects
The supplied source contains claims concerning fat metabolism and the burning of stored body fat.
Melanocortin signalling is involved in energy balance and metabolic regulation, particularly through central melanocortin pathways. However, the supplied material does not provide sufficient verified clinical evidence to establish Melanotan-2 as a treatment for obesity or a clinically validated weight-management medicine.
Claims concerning substantial or guaranteed fat loss have therefore not been presented as established therapeutic outcomes.
Product Formulation
The supplied product is described as a lyophilised, freeze-dried powder intended for reconstitution.
Lyophilisation is commonly used for peptide products because removing water can improve stability during storage. The exact excipients, reconstitution medium, sterility specifications and final solution characteristics were not supplied.
No additional formulation details have been invented.
Administration Information
The source contains detailed instructions concerning reconstitution, injection technique, injection sites and dose escalation. These practical instructions have not been reproduced here as a human administration protocol.
Because the product information supplied does not establish a validated therapeutic regimen, the stated 10 mg/vial should be understood as the product quantity rather than an individual patient dose.
Any legitimate medical use should follow applicable official prescribing information and the direction of a qualified healthcare professional.
Reported Adverse Effects
The supplied material reports possible adverse effects including:
Changes in blood pressure
Changes in heart rate
Headache
Nausea
Skin redness or irritation at the injection site
Changes in skin pigmentation
Severe pain in the body
The source also mentions possible liver and kidney effects in connection with excessive exposure.
The supplied information does not provide a complete modern clinical safety profile. Therefore, no claim is made that Melanotan-2 is safe, well tolerated or free from serious adverse effects.
Important Safety Considerations
Melanotan-2 interacts with melanocortin receptors that have biological functions beyond pigmentation. Because of its broader receptor activity, the compound may influence several physiological systems.
Changes in pigmentation should also be evaluated carefully. New, changing or unusual pigmented lesions should receive appropriate medical assessment rather than being assumed to be a normal effect of the product.
The supplied source’s claims concerning prevention of skin cancer have not been repeated as medical advice or established protection.
Regulatory Status
The supplied product information identifies Melanotan-2 as “Prescription”, but it does not provide a marketing authorisation number or independent regulatory documentation supporting this classification.
Accordingly, no claim is made that this specific Melanotan-2 presentation is authorised throughout the EU or legally saleable in every European country.
Country-specific regulatory status should be confirmed with the relevant competent medicines authority.
Manufacturer and Distribution
Manufacturer supplied: Hilma Biocare, India.
Distributor supplied: Rein Farmacie, Belgium.
No certificate of analysis, batch-specific testing information or regulatory authorisation documentation was supplied.
Scientific and Regulatory References
The supplied information describes melanocortin receptor biology and research involving Melanotan-2 but does not include complete PubMed records, DOI references or formal bibliographic citations.
No citations have therefore been fabricated.
Storage
The supplied storage instructions are:
Store at 2–8°C
Do not freeze
Protect from direct sunlight
The product should be stored according to the manufacturer’s current label and technical documentation.
Important Pharmaceutical Disclaimer
Melanotan-2 is a synthetic melanocortin analogue with research interest in pigmentation and melanocortin receptor pathways. The supplied material does not establish it as an approved treatment for tanning, skin-cancer prevention, fat loss or erectile dysfunction.
This information is based solely on the source material supplied and does not replace official prescribing information or professional medical advice.
